CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
Losartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001741
NCT00001741Phase 1Completed

Study of Vascular Responsiveness in Subjects With Polymorphisms of the Angiotensin II Type I Receptor Gene

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Nov 4, 1999·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating Losartan for Cardiovascular Disease. Completed, across 1 site.

Detailed Summary

The renin angiotensin system is a complex process involving hormones and enzymes that regulate blood volume and blood pressure. The hormone angiotensin II is responsible for making blood vessels narrow or constrict. Angiotensin II is found in the blood and can attach to special sites called receptors on blood vessel walls. These receptors are programmed to accept angiotensin II and cause a constriction of the blood vessel. This function is found in the genetic information of each individual person. Occasionally patients have changes in their genes related to angiotensin II receptors. These changes may result in the receptors acting differently to angiotensin II, which may affect the function of blood vessels. This study is designed to improve researchers understanding of the physiological effects on blood vessels associated with mutations of the genes responsible for angiotensin II receptor function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartNov 1, 1997
Study CompletionApr 1, 2003
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

Losartandrug